Skip to content

Study · Non-randomized trial · n = 10 · 2010

5 results

Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects.

Okano M, Nishitani Y, Sato M, Ikekita A, Kageyama S

Drug testing and analysis1 Nov 2010Cited by 22 (Europe PMC)

PMID21249726 (opens in a new tab)DOI10.1002/dta.166 (opens in a new tab)PepBankPUB-21249726
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Japanese men, intravenous GHRP‑2 alone increased recombinant GH (recGH) concentrations as read by the isoform differential immunoassay.

    In plain wordsIn Japanese men, GHRP‑2 raised both the recombinant-GH and the pituitary-GH readings in the doping test.

    Peptide
    GHRP-2
    Outcome
    IncreaseRecombinant GH concentration after GHRP-2
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 μg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Because GHRP-2 dose led to increases in concentrations of both recombinant GH (recGH) and pituitary GH (pit GH), no significant change in the Rec/Pit ratio was observed (P > 0.05).
    1 context sentence
    Summary · context
    In this study, a reference population (n=100) was used, with 0.04 mg/kg rhGH subcutaneous administration (n=5), 100 μg of GHRP-2 intravenous administration (n=10) and 0.04 mg/kg rhGH combined with 100 μg of GHRP-2 (n=10) in Japanese male subjects.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Japanese men, intravenous GHRP‑2 increased pituitary GH concentrations.

    In plain wordsIn Japanese men, GHRP‑2 raised the body's pituitary GH levels.

    Peptide
    GHRP-2
    Outcome
    IncreasePituitary GH concentration after GHRP-2
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 μg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Because GHRP-2 dose led to increases in concentrations of both recombinant GH (recGH) and pituitary GH (pit GH), no significant change in the Rec/Pit ratio was observed (P > 0.05).
    1 context sentence
    Summary · context
    In this study, a reference population (n=100) was used, with 0.04 mg/kg rhGH subcutaneous administration (n=5), 100 μg of GHRP-2 intravenous administration (n=10) and 0.04 mg/kg rhGH combined with 100 μg of GHRP-2 (n=10) in Japanese male subjects.
  3. 03HumanNon-randomized trialEfficacy outcome

    In Japanese men, GHRP‑2 alone caused no significant change in the Rec/Pit ratio (P > 0.05).

    In plain wordsIn Japanese men, GHRP‑2 alone did not significantly change the ratio used to detect growth hormone doping.

    Peptide
    GHRP-2
    Outcome
    No significant changeRec/Pit ratio after GHRP-2 alone
    Study

    n = 10

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 μg · intravenousAs given in this study (human).

    Source sentences

    Summary
    Because GHRP-2 dose led to increases in concentrations of both recombinant GH (recGH) and pituitary GH (pit GH), no significant change in the Rec/Pit ratio was observed (P > 0.05).
    1 context sentence
    Summary · context
    In this study, a reference population (n=100) was used, with 0.04 mg/kg rhGH subcutaneous administration (n=5), 100 μg of GHRP-2 intravenous administration (n=10) and 0.04 mg/kg rhGH combined with 100 μg of GHRP-2 (n=10) in Japanese male subjects.
  4. 04HumanNon-randomized trialEfficacy outcome

    In Japanese men, GHRP‑2 given with rhGH lowered the Rec/Pit ratio to 39.9-43.9% of the elevated ratio from rhGH alone.

    In plain wordsIn Japanese men, adding GHRP‑2 to rhGH lowered the doping-detection ratio compared with rhGH alone, which can mask doping.

    Peptide
    GHRP-2
    Outcome
    DecreaseRec/Pit ratio with GHRP-2 added to rhGH
    Study

    n = 10

    Comparator
    rhGH alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    100 μg · intravenousAs given in this study (human).

    Measurements

    Rec/Pit ratio versus rhGH alone
    39.9 to 43.9%
    rhGH plus GHRP-2

    Source sentences

    Summary
    In a combined administration study, after GHRP-2 dose the Rec/Pit ratios decreased to 39.9-43.9% compared with the elevated ratio caused by the rhGH dose
    1 context sentence
    Summary · context
    In this study, a reference population (n=100) was used, with 0.04 mg/kg rhGH subcutaneous administration (n=5), 100 μg of GHRP-2 intravenous administration (n=10) and 0.04 mg/kg rhGH combined with 100 μg of GHRP-2 (n=10) in Japanese male subjects.
  5. 05HumanNon-randomized trialPharmacokinetics

    In Japanese men, GHRP‑2 and its metabolite AA-3 were detected in urine by LC-MS/MS during the periods when the Rec/Pit ratio was masked.

    In plain wordsIn Japanese men, urine tests found GHRP‑2 and its breakdown product AA-3 while the ratio test was masked.

    Peptide
    GHRP-2
    Outcome
    Not applicableUrine detection of GHRP-2 and metabolite AA-3
    Study

    n: not reported in source

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    100 μg · intravenousAs given in this study (human).

    Source sentences

    Summary
    The analysis of GHRP-2 was found to be suitable for compensating for the disadvantages of the isoform differential immunoassay because GHRP-2 and its metabolite (AA-3) in urine could be detected during the periods of masking of the Rec/Pit ratio by means of liquid chromatography/tandem mass spectrometry.
    1 context sentence
    Summary · context
    In this study, a reference population (n=100) was used, with 0.04 mg/kg rhGH subcutaneous administration (n=5), 100 μg of GHRP-2 intravenous administration (n=10) and 0.04 mg/kg rhGH combined with 100 μg of GHRP-2 (n=10) in Japanese male subjects.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.